Waters Corporation (WAT) Stock Analysis 2026

HealthcareDiagnostics & Research
$480.07
as of 2026-10-29
+36.6% (52-week)50D MA $388.12  |  200D MA $360.19

BriMind AI Score

Proprietary
55
Moderate
Price CAGR
12.4%
1Y Return
+26.2%
Analyst Upside
-3.1%
Rev Growth
113.4%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$507.35+5.7% potential
Bear Case
$344.22
Bull Case
$616.49
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($548.83) and Wall Street's consensus target ($465.86).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

WAT Revenue & Profitability Breakdown

This chart shows how WAT's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$4.64B
Cost of Revenue
-$2.03B
Gross Profit
$2.62B56.3% margin
Operating Expenses
-$2.18B
Operating Income
$437.6M9.4% margin
Tax & Other
-$270.9M
Net Income
$166.6M3.6% margin
Gross Margin
56.3%
Operating Margin
9.4%
Net Margin
3.6%
EBITDA Margin
34.8%

Key Financial Metrics

Waters Corporation trades at a trailing P/E of 105.25x, generates $-142.1M in free cash flow, runs a debt/equity ratio of 36.05, and converts shareholder equity into profit at a 1.9% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$40.72B
Enterprise Value
$22.06B
P/E (Trailing)
105.25
P/E (Forward)
25.06
PEG Ratio
1.81
EV / EBITDA
21.25
Price / Sales
7.01
Price / Book
10.65
Revenue
$4.64B
Revenue Growth
113.4%
Earnings Growth
-3.1%
EBITDA
$1.04B
Gross Margin
56.3%
Operating Margin
9.4%
Net Margin
3.6%
Return on Equity
1.9%
Return on Assets
3.6%
Free Cash Flow
$-142.1M
Total Cash
$382.9M
Total Debt
$1.54B
Debt / Equity
36.05
Current Ratio
1.86
Quick Ratio
1.05
Beta
1.18
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
0.1%
Inst. Ownership
102.3%
Short % Float
3.7%
Book Value / Share
$154.70

Wall Street Analyst Consensus

19 analysts covering Waters Corporation currently lean toward a Hold rating, with a mean 12-month price target of $439.48 (-8.5% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingHold(19 analysts)
SellStrong Buy
Low Target$343.11-28.5%
Mean Target$439.48-8.5% upside
High Target$460.00+-4.2%

Technical Price Signals

WAT is currently in a golden cross pattern, trading above its 50-day average of $388.12 and above its 200-day average of $360.19. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$480.07
50-Day MA
$388.12
▲ Price above
200-Day MA
$360.19
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Further Reading

Research and guides that put WAT’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Market TheoryThe Stock-Split Pop Is a Myth: What 39 Real Splits Actually DidMarket Theory10-Year Treasury Yield Hits 19-Year High: What 5.2% Means for StocksRisk ManagementBest ETFs for a Recession-Proof Portfolio in 2026FundamentalsHow to Read a 10-K Annual Report: Complete Investor Guide

More Healthcare Stock Analysis

In-depth reports on companies operating alongside WAT — business models, bull and bear cases, and the metrics that matter.

TMOThermo Fisher Scientific Inc.Diagnostics & ResearchDHRDanaher CorporationDiagnostics & ResearchNTRANatera, Inc.Diagnostics & ResearchALNYAlnylam Pharmaceuticals, Inc.BiotechnologyPRVAPrivia Health Group, Inc.Health Information ServicesMDTMedtronic plcMedical DevicesCRSPCRISPR Therapeutics AGBiotechnologyEWEdwards Lifesciences CorporationMedical Devices

Unlock the Full WAT Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis